IN-VITRO ANTI-DIABETIC EVALUATION OF NAGAVANGA PARPAM BY ALPHA AMYLASE AND ALPHA GLUCOSIDASE ENZYME INHIBITION ASSAY

Background: Diabetes mellitus remains a global health challenge, with postprandial hyperglycemia being a key therapeutic target. Nagavanga Parpam (NP), a classical Siddha herbo mineral preparation containing Naagam(zinc) velvangam(tin) and extract of Pandanus odorattissimus, has been traditionally used for metabolic disorders. This study aims to scientifically validate its anti-diabetic potential. Methods: In-vitro enzyme inhibition assays against α-amylase and α-glucosidase were conducted using NP at varying concentrations (100–500 μg/ml), with Acarbose as the standard reference. Percentage inhibition and IC₅₀ values were determined. Results: NP exhibited dose-dependent inhibition of α-amylase (maximum 30.83 ± 1.53%, IC₅₀ = 804.1 ± 48.5 μg/ml) and α-glucosidase (maximum 25.43 ± 3.76%, IC₅₀ = 990.8 ± 145.3 μg/ml). Compared to Acarbose, NP showed moderate potency but measurable activity. Conclusion: The findings highlight the potential role of NP in glycemic control, supporting its further evaluation in preclinical and clinical models.